Cell and Gene Therapy Manufacturing Services Market Size & Share Analysis - Growth Trends & Forecasts (2023 - 2028)

Cell & Gene Therapy Manufacturing Services Market Analysis

The cell and gene therapy manufacturing services market is projected to register a CAGR of 12.5% during the forecast period (2022-2027).

During the COVID-19 pandemic, the cell and gene therapy manufacturing services market was adversely affected. There were two primary reasons for that, the limited running capacity protocols introduced by the governments and the disruption of supply chain and logistics processes. According to the Coronavirus Treatment Acceleration Program (CTAP) 2020 by the United States Food and Drug Administration, COVID-19-related therapies have cell therapy products, including cellular immunotherapies and other types of autologous and allogeneic cells, such as stem cells, and related products. Thus, with the treatment of COVID-19 with cell therapy products, the demand for manufacturing services increases, which is expected to significantly impact market growth. Furthermore, in April 2022, the United States Food and Drug Administration (FDA) granted clearance to BioCardia’s Investigational New Drug (IND) application to commence a Phase I/II clinical trial of COVID-19 stem cell therapy, BCDA-04, in adults recovering from COVID-19-linked acute respiratory distress syndrome (ARDS). These new IND applications in the treatment of COVID-19 will help to increase contract manufacturing services among companies.

Certain factors that are driving the market growth include the high prevalence of cancer and other target diseases and Increasing R&D investments in pharmaceutical companies. International Agency for Research on Cancer (IARC) updated GLOBOCAN 2020 with new estimates about the global cancer burden, which indicates that the number increased to 19.3 million cases. This new study suggests that more than 50 million people are living five years with a cancer diagnosis. Some of the common factors for increasing cancer cases globally are aging populations and socio-economic risk factors. Additionally, as per the same source mentioned above, breast cancer represents 1 in 4 cancers diagnosed among women globally. Due to this, for the first time, female breast cancer has become the most commonly diagnosed cancer across the world, surpassing lung cancer because of its high prevalence in low- and middle-income countries (LMICs). Since oncology is one of the most complicated disorders known to man, cell and gene therapy is one of the fields that shows huge potential in the treatment of cancer. Cancer treatment can be done via three different gene therapy treatment approaches immunotherapy, gene transfer, and oncolytic virotherapy. As the cases will increase, the reliance on gene therapy would also increase, thus, boosting the growth of the market. Furthermore, as per the report published by the Journal of Orthopedic Surgery and Research in October 2021 titled "The Global Prevalence of Osteoporosis in the World: A Comprehensive Systematic Review and Meta-analysis," the prevalence of osteoporosis in the world was reported to be 18.3%. Stem cell therapy for osteoporosis could potentially reduce the susceptibility to fractures. Thus, with the rising burden of orthopedic disorders, the demand for cell and gene therapy manufacturing services is also expected to grow.

Similarly, there is a huge increase in research and development of cell and gene therapy products in pharmaceutical and biotechnology companies. According to the United States Food and Drug Administration (USFDA), there is a huge surge in cell and gene therapy products entering early development. Due to the aforementioned factors, the market is estimated to witness a healthy growth rate during the forecast period.

Thus the above-mentioned factors are expected to drive the growth of the studied market during the forecast period. 

Cell & Gene Therapy Manufacturing Services Market Trends

This section covers the major market trends shaping the Cell & Gene Therapy Manufacturing Services Market according to our research experts:

The Allogeneic Segment is Expected to Hold a Major Market Share in the Cell Therapy Segment

Cell & Gene Therapy Manufacturing Services Industry Segmentation

As per the scope of this report, cell therapy aims to treat disorders and diseases by restoring or changing certain groups of cells or by providing cells to carry therapy through the body. With cell therapy, cells are formed or modified outside the body before being introduced into the patient. The cells may derive from the patient (autologous cells) or a donor (allogeneic cells). Gene therapy aims to treat disorders by replacing or introducing genes into cells— either inside the body (in vivo) or outside of the body (ex vivo). The Cell and Gene Therapy Manufacturing Services Market is segmented by Type (Cell Therapy (Allogeneic, Autologous, and Viral Vector) and Gene Therapy (Non-viral Vectors and Viral Vectors)), Application (Clinical Manufacturing and Commercial Manufacturing), Indication (Oncology Diseases, Cardiovascular Diseases, Orthopedic Diseases, Ophthalmology Diseases, Central Nervous System Disorders, Infectious Diseases, and Other Indications), End User (Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, and Other End Users), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.